Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer

被引：0
|
作者：
Abraham, Jame
Mechcatie, Elizabeth
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 03期
关键词：
D O I：
10.12788/jcso.0113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：83 / 86
页数：4
相关论文
共 50 条
  • [31] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [32] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Xinming Song
    Pintian Wang
    Ruiling Feng
    Mandika Chetry
    E. Li
    Xiaohua Wu
    Zewa Liu
    Shasha Liao
    Jing Lin
    Clinical and Translational Oncology, 2024, 26 : 389 - 397
  • [33] High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
    Voutsadakis, Ioannis A.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [34] Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
    Song, Xinming
    Wang, Pintian
    Feng, Ruiling
    Chetry, Mandika
    Li, E.
    Wu, Xiaohua
    Liu, Zewa
    Liao, Shasha
    Lin, Jing
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 389 - 397
  • [35] Clinical implications of molecular heterogeneity in highly proliferative, ER-positive, HER2-negative breast cancer
    Bianchini, G.
    Pusztai, L.
    Kelly, C. M.
    Iwamoto, T.
    Callari, M.
    Symmans, W. F.
    Gianni, L.
    CANCER RESEARCH, 2012, 72
  • [36] Effective sequence of endocrine therapy for ER-positive and HER2-negative metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Tashima, Rumiko
    Fujisue, Mamiko
    Nakano, Masahiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
    Hohmann, L.
    Sigurjonsdottir, K.
    Bosch, A.
    Nacer, D. F.
    Veerla, S.
    Hakkinen, J.
    Vallon-Christersson, J.
    Borg, A.
    Memari, Y.
    Davies, H.
    Nik-Zainal, S.
    Staaf, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S310 - S311
  • [38] Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
    Francesca Galardi
    Francesca De Luca
    Chiara Biagioni
    Ilenia Migliaccio
    Giuseppe Curigliano
    Alessandro M. Minisini
    Martina Bonechi
    Erica Moretti
    Emanuela Risi
    Amelia McCartney
    Matteo Benelli
    Dario Romagnoli
    Silvia Cappadona
    Stefano Gabellini
    Cristina Guarducci
    Valerio Conti
    Laura Biganzoli
    Angelo Di Leo
    Luca Malorni
    Breast Cancer Research, 23
  • [39] The numbers of Foxp3 positive cells in simultaneous bilateral ER-positive and HER2-negative breast cancer
    Goto, R.
    Hirota, Y.
    Aruga, T.
    Horiguchi, S.
    Tazawa, S.
    Yamashita, T.
    Kuroi, K.
    Nakamura, S.
    Takimoto, M.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S20 - S21
  • [40] Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
    Galardi, Francesca
    De Luca, Francesca
    Biagioni, Chiara
    Migliaccio, Ilenia
    Curigliano, Giuseppe
    Minisini, Alessandro M.
    Bonechi, Martina
    Moretti, Erica
    Risi, Emanuela
    McCartney, Amelia
    Benelli, Matteo
    Romagnoli, Dario
    Cappadona, Silvia
    Gabellini, Stefano
    Guarducci, Cristina
    Conti, Valerio
    Biganzoli, Laura
    Di Leo, Angelo
    Malorni, Luca
    BREAST CANCER RESEARCH, 2021, 23 (01)
12345